Loading clinical trials...

Research on Probiotics in Improving Obesity | Clinical Trials | Clareo Health

COMPLETEDNA

Research on Probiotics in Improving Obesity

Effectiveness and Safety of Inactivated Akkermansia Muciniphila Akk11 for Weight and Energy Metabolism in Obesity/Overweight: a Randomized, Double-blind, Placebo-controlled Trial

NCT06964919•Wecare Probiotics Co., Ltd.

View on ClinicalTrials.gov

Summary

Assess the effects of Akkermansia muciniphila Akk11 heat - killed bacteria capsules compared to a placebo on body composition indicators (weight, BMI, body fat rate, waist - hip ratio (WC), wrist circumference, visceral fat area, basal metabolic rate) and blood lipid concentrations (total cholesterol (TC), low - density lipoprotein (LDL), high - density lipoprotein (HDL), triglycerides (TG)) in overweight/obese adults.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•1. A body mass index (BMI) of ≥24 kg/m²;
•2. Willingness to provide written informed consent to participate in the study;
•3. Agreement to adhere to the study protocol and restrictions, including a low-carbohydrate, energy-restricted diet;
•4. No plans for conception from 14 days before screening until 6 months after the trial, with a commitment to using effective contraception.

Exclusion Criteria

•1. Use of products similar to the test product in the near term that may affect the results;
•2. Presence of mental or neurological disorders, celiac disease, lactose intolerance, or allergies;
•3. Pregnant, breastfeeding, or planning pregnancy;
•4. Irritable Bowel Syndrome (IBS), Ulcerative Colitis, Hepatic Cirrhosis, or Diabetes Mellitus;
•5. Antibiotic use within the past three months;
•6. Failure to consume the test product as required or attend follow-ups on time, making efficacy assessment impossible;
•7. Smoking more than 10 cigarettes a day;
•8. Allergy to probiotic products;
•9. Other participants deemed unsuitable for the study by the investigator.

Locations (1)

The School of Food and Bioengineering, Henan University of Science and Technolog

Luoyang, Henan, China

Key Dates

Start Date

March 10, 2025

Primary Completion Date

December 30, 2025

Completion Date

January 20, 2026

Last Updated

January 29, 2026

Enrollment

ACTUAL participants

Conditions

Obesity

Interventions

Probiotic

DIETARY_SUPPLEMENT

Placebo

DIETARY_SUPPLEMENT

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

NCT01143454

Metabolic DiseaseObesity+4 more

View study

RECRUITINGNA

Multi-Acupoint Laser Therapy for Body Shape and Composition in Obese Menopausal Women

NCT07472881

MenopausePerimenopause+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 29, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Research on Probiotics in Improving Obesity

Inclusion Criteria

Exclusion Criteria

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

Multi-Acupoint Laser Therapy for Body Shape and Composition in Obese Menopausal Women

Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial

Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose

Protein Supplementation Intervention on Body Weight

iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) vs Optimized Lifestyle Intervention for Weight Loss